Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

58.74USD
12:55pm EDT
Price Change (% chg)

$0.04 (+0.07%)
Prev Close
$58.70
Open
$58.52
Day's High
$58.85
Day's Low
$58.40
Volume
94,429
Avg. Vol
319,164
52-wk High
$64.85
52-wk Low
$55.16

DGX.N

Chart for DGX.N

About

Quest Diagnostics Incorporated (Quest Diagnostics), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $8,915.72
Shares Outstanding (Mil.): 151.89
Dividend: 0.30
Yield (%): 2.04

Financials

  DGX.N Industry Sector
P/E (TTM): 17.59 23.62 37.87
EPS (TTM): 3.34 -- --
ROI: 7.20 7.46 18.70
ROE: 13.40 11.89 19.53
Search Stocks

Quest Diagnostics reports third profit miss in a row

- Laboratory tests provider Quest Diagnostics Inc's results missed analysts' expectations for the third straight quarter, hurt by a cut in Medicare reimbursements.

18 Jul 2013

Quest Diagnostics profit misses estimates

July 18 - Laboratory tests provider Quest Diagnostics Inc's results missed analysts' expectations for the third straight quarter, hurt by a cut in Medicare reimbursements.

18 Jul 2013

Quest profit misses estimates, deals to drive growth

- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.

17 Apr 2013

Quest profit misses estimates, deals to drive growth

- Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.

17 Apr 2013

UPDATE 2-Quest profit misses estimates, deals to drive growth

April 17 - Laboratory tests provider Quest Diagnostics Inc, whose earnings have been hurt by Medicare reimbursement cuts, said growth this year will be driven by acquisitions.

17 Apr 2013

Quest first quarter profit misses estimates

- Laboratory tests provider Quest Diagnostics Inc's quarterly profit missed analysts estimates as Medicare reimbursement cuts ate into its margins, sending its shares down 4 percent before the bell.

17 Apr 2013

Quest 1st-qtr profit misses estimates

April 17 - Laboratory tests provider Quest Diagnostics Inc's first-quarter profit missed Wall Street's average estimate as Medicare reimbursement cuts ate into its revenue.

17 Apr 2013

UPDATE 2-Quest CFO to leave as company restructures

March 14 - Laboratory tests provider Quest Diagnostics on Thursday said its Chief Financial Officer Robert Hagemann will leave at the end of May as the company continues a restructuring aimed at returning to revenue growth.

14 Mar 2013

Quest CFO to step down at the end of May

March 14 - Laboratory tests provider Quest Diagnostics said Chief Financial Officer Robert Hagemann will leave the company at the end of May.

14 Mar 2013

TEXT-Fitch affirms Quest Diagnostics IDR, outlook revised to stable

Feb 22 - Fitch Ratings has affirmed Quest Diagnostics, Inc.'s (Quest) Issuer Default Rating (IDR) at 'BBB+'. A complete list of ratings is provided at the end of this release. The ratings apply to approximately $3.36 billion of outstanding debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS Debt Leverage Within Goal Quest has reduced leverage (total debt to EBITDA) during 2012 into its stated target range of 2.0 times (x) to 2.25x, a level Fitch considers to be c

22 Feb 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks